Treatment of Behcet's Disease: An Algorithmic Multidisciplinary Approach

被引:45
作者
Alpsoy, Erkan [1 ]
Leccese, Pietro [2 ,3 ]
Emmi, Giacomo [4 ]
Ohno, Shigeaki [5 ,6 ]
机构
[1] Akdeniz Univ, Sch Med, Dept Dermatol & Venereol, Antalya, Turkey
[2] San Carlo Hosp Potenza, Rheumatol Dept Lucania, Rheumatol Inst Lucania, Potenza, Italy
[3] Madonna Grazie Hosp Matera, Matera, Italy
[4] Univ Firenze, Dept Expt & Clin Med, Florence, Italy
[5] Aishin Mem Hosp, Ophthalmol Ctr, Sapporo, Hokkaido, Japan
[6] Hokkaido Univ, Dept Ophthalmol, Fac Med, Grad Sch Med, Sapporo, Hokkaido, Japan
关键词
algorithms; therapeutics; morbidity; mortality; Behç et' s disease; ANTI-TNF-ALPHA; PULMONARY-ARTERY INVOLVEMENT; DAGGER-ETS DISEASE; DOUBLE-BLIND TRIAL; CYCLOSPORINE-A; INTESTINAL INVOLVEMENT; MUCOCUTANEOUS LESIONS; CLINICAL-FEATURES; APHTHOUS ULCERS; OCULAR LESIONS;
D O I
10.3389/fmed.2021.624795
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Behcet's disease (BD) is a chronic, relapsing inflammatory, multisystem disease of unknown etiology. The disease has a wide clinical spectrum of mucocutaneous lesions and ocular, vascular, articular, neurologic, gastrointestinal and cardiac involvement. Although the number of effective drugs used in the disease's treatment has increased in recent years, BD is still associated with severe morbidity because of mainly mucocutaneous, articular and ocular symptoms and an increased mortality because of large vessel, neurological, gastrointestinal and cardiac involvement. Many factors are associated with a more serious course, such as male gender and a younger age of onset. While the severity of the disease is more pronounced in the first years of the disease, it decreases in most patients after the age of forties. The primary goal of treatment should be the prevention of irreversible organ damage. Therefore, early diagnosis and appropriate treatment and close follow-up are mandatory to reduce the morbidity and mortality of the disease. Treatment varies depending on the organ involved and the severity of the involvement. For all these reasons, the treatment should be personalized and arranged with a multidisciplinary approach according to the organs involved. Treatment is mainly based on suppression of the inflammatory attacks of the disease using local and systemic immunomodulatory and immunosuppressive drugs. In this review, based on the mainly controlled studies and personal experience in clinical practice and basic research in this field, we propose a stepwise, symptom-based, algorithmic approach for the management of BD with a holistic perspective.
引用
收藏
页数:11
相关论文
共 109 条
  • [31] DAVIES UM, 1988, BRIT J RHEUMATOL, V27, P300
  • [32] Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients
    Desbois, A. C.
    Biard, L.
    Addimanda, O.
    Lambert, M.
    Hachulla, E.
    Launay, D.
    Ackermann, F.
    Perard, L.
    Hot, A.
    Maurier, F.
    Mausservey, C.
    Bernard, F.
    Noel, N.
    Alric, L.
    Mirault, T.
    Cohen, F.
    Boussouar, S.
    Resche-Rigon, M.
    Cacoub, P.
    Saadoun, D.
    [J]. CLINICAL IMMUNOLOGY, 2018, 197 : 54 - 59
  • [33] Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials
    Dick, Andrew D.
    Tugal-Tutkun, Ilknur
    Foster, Stephen
    Zierhut, Manfred
    Liew, S. H. Melissa
    Bezlyak, Vladimir
    Androudi, Sofia
    [J]. OPHTHALMOLOGY, 2013, 120 (04) : 777 - 787
  • [34] Papulopustular skin lesions are seen more frequently in patients with Behcet's syndrome who have arthritis: a controlled and masked study
    Diri, E
    Mat, C
    Hamuryudan, V
    Yurdakul, S
    Hizli, N
    Yazici, H
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (11) : 1074 - 1076
  • [35] EFFECT OF CYCLOSPORINE-A ON THE HEARING-LOSS IN BEHCETS-DISEASE
    ELIDAN, J
    COHEN, E
    LEVI, H
    BENEZRA, D
    [J]. ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1991, 100 (06) : 464 - 468
  • [36] Butyrate-Rich Diets Improve Redox Status and Fibrin Lysis in Behcet's Syndrome
    Emmi, Giacomo
    Bettiol, Alessandra
    Niccolai, Elena
    Ramazzotti, Matteo
    Amedei, Amedeo
    Pagliai, Giuditta
    Taddei, Niccolo
    Sofi, Francesco
    Fiorillo, Claudia
    Prisco, Domenico
    Becatti, Matteo
    [J]. CIRCULATION RESEARCH, 2021, 128 (02) : 278 - 280
  • [37] Stem-Cell-Derived Circulating Progenitors Dysfunction in Behcet's Syndrome Patients Correlates With Oxidative Stress
    Emmi, Giacomo
    Mannucci, Amanda
    Argento, Flavia Rita
    Silvestri, Elena
    Vaglio, Augusto
    Bettiol, Alessandra
    Fanelli, Alessandra
    Stefani, Laura
    Taddei, Niccolo
    Prisco, Domenico
    Fiorillo, Claudia
    Becatti, Matteo
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [38] Behcet's syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments
    Emmi, Giacomo
    Prisco, Domenico
    [J]. INTERNAL AND EMERGENCY MEDICINE, 2019, 14 (05) : 639 - 643
  • [39] Behcet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils
    Emmi, Giacomo
    Becatti, Matteo
    Bettiol, Alessandra
    Hatemi, Gulen
    Prisco, Domenico
    Fiorillo, Claudia
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [40] Vascular Behcet's syndrome: an update
    Emmi, Giacomo
    Bettiol, Alessandra
    Silvestri, Elena
    Di Scala, Gerardo
    Becatti, Matteo
    Fiorillo, Claudia
    Prisco, Domenico
    [J]. INTERNAL AND EMERGENCY MEDICINE, 2019, 14 (05) : 645 - 652